Veranova A CDMO that manages complexity with confidence

Veranova A CDMO that manages complexity with confidence

X

[{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rubedo Life Sciences Closes $12M Seed Financing Led by Khosla Ventures","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Rubedo Life Sciences"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Initium Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Through Strategic Collaboration with GenScript ProBio, Initium Therapeutics Plans to Utilize GenScript ProBio's Berkeley Lights Beacon Platform to Expand Their Antibody Drug Pipeline","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"GenScript ProBio"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI Achieves Second Major Collaboration Milestone With Novel Idiopathic Pulmonary Fibrosis Target Selected For AstraZeneca\u2019s Portfolio","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"BenevolentAI"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI Achieves Third Milestone in Its AI-enabled Drug Discovery Collaboration With AstraZeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"BenevolentAI"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

BenevolentAI

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

BenevolentAI Achieves Third Milestone in Its AI-enabled Drug Discovery Collaboration With AstraZeneca

Details:

This is the third novel target from the collaboration that has been identified using the Benevolent Platform™ across two disease areas, IPF and chronic kidney disease, and subsequently validated and selected for portfolio entry by AstraZeneca.

Lead Product(s): Undisclosed

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Undisclosed

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 17, 2022

ASK
US

Upload
your Pipeline Activity

BenevolentAI

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

BenevolentAI Achieves Second Major Collaboration Milestone With Novel Idiopathic Pulmonary Fibrosis Target Selected For AstraZeneca’s Portfolio

Details:

The innovative collaboration structure scientists and technologists from the two companies working side-by-side, combining the Benevolent Platform™ — an AI-driven drug discovery platform and biomedical knowledge graph with AstraZeneca’s scientific expertise and rich datasets.

Lead Product(s): Undisclosed

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Undisclosed

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration December 15, 2021

ASK
US

Upload
your Pipeline Activity

GenScript ProBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Through Strategic Collaboration with GenScript ProBio, Initium Therapeutics Plans to Utilize GenScript ProBio's Berkeley Lights Beacon Platform to Expand Their Antibody Dru...

Details:

The strategic collaboration between the two companies will allow Initium Therapeutics to expand their antibody drug pipeline using GenScript ProBio's ultra-rapid, high-efficient Berkeley Lights Beacon platform.

Lead Product(s): Antibody-based therapeutics

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Large molecule

Partner/Sponsor/Collaborator: Initium Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration December 07, 2020

ASK
US

Upload
your Pipeline Activity

Rubedo Life Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Rubedo Life Sciences Closes $12M Seed Financing Led by Khosla Ventures

Details:

The funding will be used to advance the company’s lead candidates in respiratory diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

Lead Product(s): Undisclosed

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Small molecule

Partner/Sponsor/Collaborator: Khosla Ventures

Deal Size: $12.0 million Upfront Cash: Undisclosed

Deal Type: Financing December 03, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY